This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Zeaxanthin
Zeaxanthin is one of three xanthophyll carotenoids that concentrate in the macula lutea to form macular pigment, a yellow spot at the back of the eye that filters blue light and quenches retinal ox…
Aliases (6)
Overview
What is Zeaxanthin?
Zeaxanthin is one of three xanthophyll carotenoids that concentrate in the macula lutea to form macular pigment, a yellow spot at the back of the eye that filters blue light and quenches retinal oxidative stress. Of the three (lutein, RR-zeaxanthin, meso-zeaxanthin), zeaxanthin and meso-zeaxanthin dominate the central fovea — the patch of retina that handles your sharpest, color-rich, daylight vision — while lutein spreads more to the peripheral macula. AREDS2 (n=4,203, 10-year follow-up via Report 28 in 2022) is the gold-standard dataset and uses 2 mg zeaxanthin paired with 10 mg lutein. Stringham 2017 (Foods, n=48 high-screen-time young adults) and Renzi-Hammond 2017 (Nutrients, n=51 healthy 18-25 yo) extend the case beyond AMD into screen-fatigue and cognitive performance in young populations — but ALL major trials test the L+Z combo, almost never zeaxanthin alone. Practical reality: you'll buy a "lutein + zeaxanthin" combo product (5:1 ratio) — true zeaxanthin standalone is rare. Verdict OPTIONAL-ADD for Dylan: high-screen night-owl + MMA athlete (chromatic contrast, glare recovery for sparring/striking) at ~$10-15/month, but the long-tail AMD payoff is 40-50 years out and orange peppers + 28 g goji berries 3x/week + eggs cover most of the need food-first.
Peptide Interactions
Co-required. Every major trial uses the combo at ~5:1 lutein:zeaxanthin ratio (10 mg:2 mg). Lutein dominates peripheral macula, zeaxanthin dominates fovea — …
Adds a third pigment that concentrates specifically at the foveal epicenter. Stringham 2017 + CREST AMD substudy support adding meso-Z for screen-heavy / vis…
Another xanthophyll, accumulates more in cornea/ciliary body than macula. Different niche. Plausibly additive for general retinal antioxidant load, especiall…
AREDS2 tested omega-3 alongside L+Z and found no additional AMD benefit BUT omega-3 also serves cardiovascular and CNS roles. DHA is structurally critical fo…
Already paired with L+Z in AREDS2 formula. Some additive antioxidant capacity. No harm; modest stacking sense.
Required cofactor for retinal metabolic enzymes; AREDS2 formula includes 25 mg zinc oxide. Standalone L+Z products may not include zinc — fine for healthy ad…
Not a "stack" but a co-administration absorption boost. Tripled bioavailability.
all fine. No mechanistic interaction.
no interaction; xanthophylls are pharmacologically inert outside the retinal/cortical antioxidant role.
(>15 mg/day) — competes with L+Z for the same intestinal transport machinery (SR-BI, CD36) and can lower L+Z absorption. Particularly avoid in smokers (lung-…
(orlistat, alli) — reduces absorption of all fat-soluble vitamins and carotenoids. Not a concern for typical biohacker.
(cholestyramine, colesevelam) — same absorption issue. Separate by ≥4 hours if used together. Irrelevant for Dylan.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Side Effects & Safety
- Common (>10% chronic users): None subjectively reported at AREDS2 doses.
- Less common (1-10%):
- Carotenodermia at ≥20-30 mg/day total carotenoid intake (sum of L + Z + meso-Z + dietary). Yellow-orange tint to palms, soles, sometimes nasolabial folds. Completely harmless, fully reversible on dose reduction. Cosmetic only. Distinguishable from jaundice by sclerae remaining white.
- Mild GI upset at very high single doses or empty-stomach dosing — rare.
- Rare-serious (<1%):
- No serious adverse events documented in AREDS2 (n=4,203, 5+ years) or in the 10-year Report 28 follow-up. Effectively zero safety signal at conventional doses.
- Specific watch period:
- First 12 weeks: no adjustments needed. If you're stacking with high-dose beta-carotene or astaxanthin AND have a smoking history, see "drug interactions" below.
- Smokers / former smokers: This is the most important caveat. AREDS1 used beta-carotene (a different carotenoid) and showed an INCREASE in lung-cancer incidence in smokers — which is why AREDS2 substituted L+Z for beta-carotene. L+Z themselves have NOT shown a lung-cancer signal (10-year Report 28 confirmed: L+Z OR 1.15 vs. beta-carotene OR 1.82). Practically: L+Z is the safe-for-smokers carotenoid choice; beta-carotene supplementation is the one to avoid. Dylan does not smoke, so this is moot, but worth knowing for cross-reference.
- Pregnancy / breastfeeding: Considered safe at dietary equivalent doses; data is observational rather than RCT-derived. Not a concern for Dylan.
- Children: AREDS2 doses have been used in children with cystic fibrosis and other fat-malabsorption conditions without adverse signal; some pediatric trials use 10 mg L + 2 mg Z (Mohn 2018, others).
- Liver disease / kidney disease: No dose adjustment needed.
- Ulcerative colitis / Crohn's: Fat malabsorption may reduce uptake; supplement during meals with most fat content.
References
AREDS2 trial — Chew et al. 2013, JAMA (PMID 23644932)
the 4,203-subject 5-year RCT establishing L+Z as the preferred carotenoid pair
View StudyAREDS2 Report 28 — 10-year follow-up — Chew et al. 2022, JAMA Ophthalmol (PMID 35653117)
10-year durability + lung-cancer safety confirmation
View StudyAREDS2 Cataract Report 4 — Chew et al. 2013 (PMID 23645227)
null finding for cataract progression
View StudyStringham et al. 2017, Foods — high-screen-time supplementation RCT (PMID 28661438)
the screen-heavy / sleep / visual-performance trial most relevant to Dylan
View StudyRenzi-Hammond et al. 2017, Nutrients — young adult cognitive RCT (PMID 29135938)
12-month L+Z in 18-25 yo with processing-speed gains
View StudyMacular pigment carotenoids cognitive function systematic review 2022 (PMID 35752349)
pooled 18-trial cognitive evidence
View StudyBone & Landrum 1997, Exp Eye Res — stereoisomer distribution in human retina (PMID 9176055)
foundational foveal-mapping paper
View StudySabour-Pickett 2013, Eye — "What is meso-zeaxanthin, and where does it come from?" (PMID 23703634)
meso-Z synthesis review
View StudyBone 2007, Nutr Metab — supplementation with all three carotenoids (PMID 17498306)
first 3-carotenoid trial
View StudyConnolly 2011, IOVS — three macular carotenoids response/safety (PMID 21979997)
dose-response confirmation
View StudyGoji Berry MPOD Trial — Li et al. 2021, Nutrients (PMID 34959963)
whole-food parity finding
View StudyZeaxanthin and Visual Function (ZVF) Study 2011 (PMID 22027699)
FDA-IND high-dose zeaxanthin in atrophic AMD
View StudyCREST design paper 2014 (PMID 24621122)
protocol for the meso-Z head-to-head trials
View StudyLinus Pauling Institute, carotenoids monograph
comprehensive textbook reference
View StudyLatest research
- metaEffect of macular pigment carotenoids on cognitive functions — systematic reviewPooled MPOD-cognition evidence — positive cognitive findings in 14 of 18 reviewed trials (RCT + observational), with strongest signal for processing speed and visual memory in young adults and older adults respectively. Mechanism likely BBB-crossing xanthophyll accumulation in frontal/occipital cortex.
- rctLong-term Outcomes of Adding Lutein/Zeaxanthin and omega-3 Fatty Acids to the AREDS Supplements on AMD Progression — AREDS2 Report 2810-year follow-up of AREDS2 cohort (n=4,203) confirmed durable benefit of lutein/zeaxanthin over beta-carotene; HR for late AMD progression 0.91 (95% CI 0.84-0.99, p=0.02) and no lung cancer signal (vs. beta-carotene OR 1.82).
- rctGoji Berry Intake Increases Macular Pigment Optical Density in Healthy Adults — Randomized Pilot Trial (Li et al.)28 g/day dried goji berries (~25 mg zeaxanthin) 5x/week for 90 days raised MPOD significantly at 0.25 and 1.75 deg eccentricities in healthy 45-65 yo adults; matched-dose lutein/zeaxanthin supplement (6 mg L + 4 mg Z) did NOT raise MPOD in same study — suggests whole-food matrix matters.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.